Prognostic value of circulating tumor DNA fraction (TF) for patients with metastatic renal cell carcinoma (mRCC).

被引：0
|
作者：
Zurita, Amado J.
Danziger, Natalie
Scott, Takara
Gjoerup, Ole
Zhong, Lei
Tukachinsky, Hanna
Ross, Jeffrey S.
Graf, Ryon
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] Fdn Med Inc, Cambridge, MA USA
[3] SUNY Upstate Med Univ, Syracuse, NY USA
[4] Fdn Med Inc, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2024.42.4_suppl.455
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
455
引用
收藏
页码：455 / 455
页数：1
相关论文
共 50 条
  • [21] Circulating tumor cell composition and molecular markers in metastasized renal cell carcinoma (mRCC)
    Gauler, T.
    Nel, I.
    Bublitz, K.
    Lazaridis, L.
    Schuler, M.
    Hoffmann, A-C
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 131 - 131
  • [22] Prognostic and predictive value of mRNA expression of mTOR and VEGF pathway members in metastatic renal cell carcinoma (mRCC).
    Nosov, Dmitry
    Voroshilova, Ekaterina
    Apanovich, Natalya
    Fedyanin, Mikhail
    Karpukhin, Alexander
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [23] DIAGNOSTIC AND PROGNOSTIC VALUE OF URINE CIRCULATING CELL-FREE DNA IN RENAL CELL CARCINOMA
    Oto, Julia
    Santillana, Noelia
    Jose Solmoirago, Ma
    Perez-Ardavin, Javier
    Vicente Sanchez-Gonzalez, Jose
    Plana, Emma
    Hervas, David
    Fernandez-Pardo, Alvaro
    Yelo, Marina
    Vera-Donoso, Cesar D.
    Martinez-Sarmiento, Manuel
    Espana, Francisco
    Navarro, Silvia
    Medina, Pilar
    JOURNAL OF UROLOGY, 2019, 201 (04): : E296 - E296
  • [24] Limited Prognostic Value of Tumor Necrosis in Patients With Renal Cell Carcinoma
    Isbarn, Hendrik
    Patard, Jean-Jacques
    Lughezzani, Giovanni
    Rioux-Leclercq, Nathalie
    Crepel, Maxime
    Cindolo, Luca
    de la Taille, Alexandre
    Zini, Laurent
    Villers, Arnauld
    Shariat, Shahrokh F.
    Bertini, Roberto
    Karakiewicz, Pierre I.
    UROLOGY, 2010, 75 (06) : 1378 - 1384
  • [25] Circulating Cell-Free DNA Levels in Patients with Metastatic Renal Cell Carcinoma
    Rouvinov, Keren
    Mermershtain, Wilmosh
    Dresler, Hadas
    Ariad, Samuel
    Riff, Reut
    Shani-Shrem, Noa
    Keizman, Daniel
    Douvdevani, Amos
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (11) : 707 - 710
  • [26] Australian Treatment Practices for Patients with Metastatic Renal Cell Carcinoma (MRCC)
    Liow, Elizabeth
    Baenziger, Olivia
    Corrente, Claudia
    Law, Nicholas
    Azad, Arun
    Shapiro, Julia
    Shapiro, Jeremy
    Weickhardt, Andrew
    Schmidt, Andrew
    Parnis, Francis
    Wong, Shirley
    Parente, Phillip
    Anton, Angelyn
    Pezaro, Carmel
    Tran, Ben
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 55 - 55
  • [27] Prognostic Value of Plasma hPG80 (Circulating Progastrin) in Metastatic Renal Cell Carcinoma
    Kohli, Manish
    Tan, Winston
    Vire, Berengere
    Liaud, Pierre
    Blairvacq, Melina
    Berthier, Frederic
    Rouison, Daniel
    Garnier, George
    Payen, Lea
    Cousin, Thierry
    Joubert, Dominique
    Prieur, Alexandre
    CANCERS, 2021, 13 (03) : 1 - 13
  • [28] PATTERNS OF CARE IN AUSTRALIAN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)
    Dai, D.
    Kanjanapan, Y.
    Kwan, E.
    Yip, D.
    Lawrentschuk, N.
    Andrews, M.
    Davis, I. D.
    Azad, A.
    Rosenthal, M.
    Wong, S.
    Arifeen, S.
    Alam, M.
    Gibbs, P.
    Tran, B.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 33 - 33
  • [29] Illustration of temporal evolution in patients with metastatic renal cell carcinoma (mRCC) using both circulating tumor DNA (ctDNA) and tissue-based genomic data.
    Zengin, Zeynep Busra
    Weipert, Caroline
    Hsu, Joann
    Salgia, Nicholas
    Hensel, Chuck
    Maughan, Benjamin Louis
    Rathi, Nityam
    Goel, Divyam
    Agarwal, Neeraj
    Choueiri, Toni K.
    Pal, Sumanta K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [30] Sunitinib safety and tolerability in patients with metastatic renal cell carcinoma (MRCC)
    Ferrari, A.
    Sabbatini, R.
    Maur, M.
    Giovannelli, S.
    Jovic, G.
    Conte, P.
    ANNALS OF ONCOLOGY, 2006, 17 : XI83 - XI83
12345